
Novartis Delays Myelofibrosis Drug Approval Following Safety Signal in MorphoSys Acquisition
Novartis’ €2.7 Billion Investment in MorphoSys Hits Setback as Safety Signal Delays Key Drug Filing Novartis’ recent acquisition of MorphoSys aimed to bring promising therapies